DK2041093T3 - Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer - Google Patents

Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer

Info

Publication number: DK2041093T3
Authority: DK; Denmark
Prior art keywords: treatment; gpr38 receptor; piperazinyl derivatives; diseases; useful
Prior art date: 2006-06-28

Application number

DK07765616.3T

Other languages

English (en)

Inventor

Darren Jason Mitchell

Jonathan Thomas Seal

Mervyn Thompson

Susan Marie Westaway

Samantha Louisa Brown

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-28

Filing date

2007-06-26

Publication date

2010-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2041093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-28 Priority claimed from GB0612844A external-priority patent/GB0612844D0/en

2007-06-14 Priority claimed from GB0711525A external-priority patent/GB0711525D0/en

2007-06-26 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-08-02 Application granted granted Critical

2010-08-02 Publication of DK2041093T3 publication Critical patent/DK2041093T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

DK07765616.3T 2006-06-28 2007-06-26 Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer DK2041093T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0612844A GB0612844D0 (en)	2006-06-28	2006-06-28	Compounds
GB0711525A GB0711525D0 (en)	2007-06-14	2007-06-14	Compounds
PCT/EP2007/056342 WO2008000729A1 (en)	2006-06-28	2007-06-26	Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases

Publications (1)

Publication Number	Publication Date
DK2041093T3 true DK2041093T3 (da)	2010-08-02

Family

ID=38476358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07765616.3T DK2041093T3 (da)	2006-06-28	2007-06-26	Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer

Country Status (29)

Country	Link
US (2)	US7700599B2 (da)
EP (1)	EP2041093B1 (da)
JP (1)	JP5028484B2 (da)
KR (1)	KR20090031688A (da)
AR (1)	AR061656A1 (da)
AT (1)	ATE465150T1 (da)
AU (1)	AU2007263712B2 (da)
BR (1)	BRPI0713443A2 (da)
CA (1)	CA2655540A1 (da)
CR (1)	CR10497A (da)
CY (1)	CY1110190T1 (da)
DE (1)	DE602007006019D1 (da)
DK (1)	DK2041093T3 (da)
EA (1)	EA015820B1 (da)
ES (1)	ES2344484T3 (da)
HR (1)	HRP20100284T1 (da)
IL (1)	IL195900A0 (da)
JO (1)	JO2645B1 (da)
MA (1)	MA30539B1 (da)
MX (1)	MX2009000110A (da)
MY (1)	MY147677A (da)
NO (1)	NO20090266L (da)
NZ (1)	NZ573450A (da)
PE (1)	PE20080345A1 (da)
PL (1)	PL2041093T3 (da)
PT (1)	PT2041093E (da)
SI (1)	SI2041093T1 (da)
TW (1)	TWI391386B (da)
WO (1)	WO2008000729A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0611907D0 (en)	2006-06-15	2006-07-26	Glaxo Group Ltd	Compounds
US8536182B2 (en)	2005-07-26	2013-09-17	Glaxo Group Limited	Benzylpiperazine derivatives and their medical use
GB0524814D0 (en) *	2005-12-05	2006-01-11	Glaxo Group Ltd	Compounds
DK2041093T3 (da) *	2006-06-28	2010-08-02	Glaxo Group Ltd	Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
GB0723317D0 (en) *	2007-11-28	2008-01-09	Glaxo Group Ltd	Compounds
CA2750699C (en)	2009-02-27	2015-12-29	Raqualia Pharma Inc.	Oxyindole derivatives with motilin receptor agonistic activity
US9452980B2 (en) *	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
JP2013518085A (ja)	2010-02-01	2013-05-20	ノバルティスアーゲー	ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh)	2010-02-02	2014-12-24	诺华股份有限公司	用作crf受体拮抗剂的环己基酰胺衍生物
JP5753179B2 (ja)	2010-09-27	2015-07-22	第一三共株式会社	シクロヘキサン誘導体化合物
US9321727B2 (en) *	2011-06-10	2016-04-26	Hoffmann-La Roche Inc.	Pyridine derivatives as agonists of the CB2 receptor
RS60825B1 (sr)	2016-03-17	2020-10-30	Hoffmann La Roche	Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
IL301556A (en) *	2020-09-25	2023-05-01	Shanghai Meiyue Biotech Dev Co Ltd	Pyrimidine carboxamide compound and application thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5385912A (en) *	1991-03-08	1995-01-31	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
JPH06211886A (ja)	1992-11-04	1994-08-02	Chugai Pharmaceut Co Ltd	エリスロマイシン誘導体
TW355711B (en)	1992-11-04	1999-04-11	Chugai Pharmaceutical Co Ltd	Erythromycin derivatives
US5593994A (en) *	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
JP3901239B2 (ja)	1996-03-13	2007-04-04	大正製薬株式会社	アリールアルカン誘導体
US5965578A (en) *	1996-04-03	1999-10-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
DE19644195A1 (de)	1996-10-24	1998-04-30	Solvay Pharm Gmbh	10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1998023629A1 (fr) *	1996-11-26	1998-06-04	Chugai Seiyaku Kabushiki Kaisha	Composes de macrolides comportant une chaine a 13 elements, medicament les contenant et leur procede de preparation
US6060491A (en) *	1997-06-19	2000-05-09	Dupont Pharmaceuticals	6-membered aromatics as factor Xa inhibitors
US5972939A (en) *	1997-10-28	1999-10-26	Ortho-Mcneil Pharmaceutical, Inc.	Cyclopentene derivatives useful as antagonists of the motilin receptor
DE19805822B4 (de)	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6165985A (en)	1998-02-13	2000-12-26	Solvay Pharmaceuticals Gmbh	11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
GB9804734D0 (en) *	1998-03-05	1998-04-29	Pfizer Ltd	Compounds
HUP0202708A3 (en) *	1999-04-15	2004-12-28	Bristol Myers Squibb Co	Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
US20020010184A1 (en) *	2000-02-18	2002-01-24	Dinsmore Christopher J.	Inhibitors of prenyl-protein transferase
US20020052380A1 (en) *	2000-02-18	2002-05-02	Dinsmore Christopher J.	Inhibitors of prenyl-protein transferase
US6392040B2 (en) *	2000-03-13	2002-05-21	Ortho-Mcneil Pharmaceutical, Inc.	Cyclopentene compounds useful as antagonists of the motilin receptor
US6423714B2 (en) *	2000-03-13	2002-07-23	Ortho Mcneil-Pharmaceutical, Inc..	Cyclohexene derivatives useful as antagonists of the motilin receptor
US6384031B2 (en) *	2000-03-13	2002-05-07	Ortho-Mcneil Pharmaceutical, Inc.	Cyclobutene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) *	2000-05-05	2003-01-28	Ortho Mcneil Pharmaceutical, Inc.	Substituted diamine derivatives useful as motilin antagonists
GB0013378D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Use of therapeutic benzamide derivatives
US7105682B2 (en) *	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
US6878714B2 (en) *	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US7102009B2 (en) *	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
EP1392679B1 (de)	2001-05-10	2005-11-02	Solvay Pharmaceuticals GmbH	Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) *	2001-07-25	2005-12-20	Amgen Inc.	Substituted piperidines and methods of use
GB0129013D0 (en) *	2001-12-04	2002-01-23	Glaxo Group Ltd	Compounds
GB0129015D0 (en) *	2001-12-04	2002-01-23	Glaxo Group Ltd	Compounds
SE0203302D0 (sv) *	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Compounds
US7223788B2 (en) *	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7262195B2 (en)	2003-09-17	2007-08-28	Bristol-Myers Squibb Company	Compounds useful as motilin agonists and method
US7338954B2 (en)	2003-09-17	2008-03-04	Bristol-Myers Squibb Company	Compounds useful as motilin agonists and method
CA2540826A1 (en) *	2003-10-01	2005-04-14	The Procter & Gamble Company	Melanin concentrating hormone antagonists
WO2005063720A1 (ja) *	2003-12-25	2005-07-14	Nippon Shinyaku Co., Ltd.	アミド誘導体及び医薬
WO2005077345A1 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Compounds for the treatment of gastro-esophageal reflux disease
WO2005077373A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
WO2005089502A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
SE0401345D0 (sv)	2004-05-25	2004-05-25	Astrazeneca Ab	Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en)	2006-06-15	2006-07-26	Glaxo Group Ltd	Compounds
US20080312209A1 (en)	2005-07-12	2008-12-18	Glaxo Group Limited	Piperazine Heteroaryl Derivatives as Gpr38 Agonists
US8536182B2 (en) *	2005-07-26	2013-09-17	Glaxo Group Limited	Benzylpiperazine derivatives and their medical use
DK2041093T3 (da) *	2006-06-28	2010-08-02	Glaxo Group Ltd	Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer

2007
- 2007-06-26 DK DK07765616.3T patent/DK2041093T3/da active
- 2007-06-26 AR ARP070102835A patent/AR061656A1/es not_active Application Discontinuation
- 2007-06-26 EA EA200970065A patent/EA015820B1/ru not_active IP Right Cessation
- 2007-06-26 MX MX2009000110A patent/MX2009000110A/es active IP Right Grant
- 2007-06-26 BR BRPI0713443-6A patent/BRPI0713443A2/pt not_active IP Right Cessation
- 2007-06-26 JP JP2009517160A patent/JP5028484B2/ja not_active Expired - Fee Related
- 2007-06-26 PE PE2007000819A patent/PE20080345A1/es not_active Application Discontinuation
- 2007-06-26 CA CA002655540A patent/CA2655540A1/en not_active Abandoned
- 2007-06-26 NZ NZ573450A patent/NZ573450A/en not_active IP Right Cessation
- 2007-06-26 SI SI200730257T patent/SI2041093T1/sl unknown
- 2007-06-26 TW TW096122969A patent/TWI391386B/zh not_active IP Right Cessation
- 2007-06-26 AU AU2007263712A patent/AU2007263712B2/en not_active Ceased
- 2007-06-26 US US11/768,339 patent/US7700599B2/en not_active Expired - Fee Related
- 2007-06-26 ES ES07765616T patent/ES2344484T3/es active Active
- 2007-06-26 DE DE602007006019T patent/DE602007006019D1/de active Active
- 2007-06-26 EP EP07765616A patent/EP2041093B1/en active Active
- 2007-06-26 PT PT07765616T patent/PT2041093E/pt unknown
- 2007-06-26 AT AT07765616T patent/ATE465150T1/de active
- 2007-06-26 KR KR1020087031612A patent/KR20090031688A/ko not_active Ceased
- 2007-06-26 JO JO2007261A patent/JO2645B1/en active
- 2007-06-26 WO PCT/EP2007/056342 patent/WO2008000729A1/en not_active Ceased
- 2007-06-26 PL PL07765616T patent/PL2041093T3/pl unknown
- 2007-06-26 HR HR20100284T patent/HRP20100284T1/hr unknown
2008
- 2008-12-11 IL IL195900A patent/IL195900A0/en unknown
- 2008-12-11 CR CR10497A patent/CR10497A/es not_active Application Discontinuation
- 2008-12-24 MY MYPI20085319A patent/MY147677A/en unknown
- 2008-12-30 MA MA31526A patent/MA30539B1/fr unknown
2009
- 2009-01-16 NO NO20090266A patent/NO20090266L/no not_active Application Discontinuation
- 2009-04-02 US US12/417,176 patent/US8853218B2/en not_active Expired - Fee Related
2010
- 2010-06-11 CY CY20101100521T patent/CY1110190T1/el unknown

Also Published As

Publication number	Publication date
EP2041093A1 (en)	2009-04-01
US8853218B2 (en)	2014-10-07
PT2041093E (pt)	2010-06-28
HRP20100284T1 (hr)	2010-06-30
AU2007263712A1 (en)	2008-01-03
CR10497A (es)	2009-03-20
JP2009541432A (ja)	2009-11-26
MX2009000110A (es)	2009-01-23
ES2344484T3 (es)	2010-08-27
MY147677A (en)	2012-12-31
BRPI0713443A2 (pt)	2012-03-06
JO2645B1 (en)	2012-06-17
CY1110190T1 (el)	2015-01-14
EA200970065A1 (ru)	2009-06-30
IL195900A0 (en)	2009-09-01
NO20090266L (no)	2009-03-17
AR061656A1 (es)	2008-09-10
DE602007006019D1 (de)	2010-06-02
PL2041093T3 (pl)	2010-09-30
TWI391386B (zh)	2013-04-01
EP2041093B1 (en)	2010-04-21
TW200817352A (en)	2008-04-16
NZ573450A (en)	2011-11-25
PE20080345A1 (es)	2008-05-29
MA30539B1 (fr)	2009-06-01
JP5028484B2 (ja)	2012-09-19
ATE465150T1 (de)	2010-05-15
WO2008000729A1 (en)	2008-01-03
US20090192160A1 (en)	2009-07-30
US20080027065A1 (en)	2008-01-31
AU2007263712B2 (en)	2012-08-30
SI2041093T1 (sl)	2010-07-30
HK1127608A1 (en)	2009-10-02
CA2655540A1 (en)	2008-01-03
EA015820B1 (ru)	2011-12-30
KR20090031688A (ko)	2009-03-27
US7700599B2 (en)	2010-04-20

Publication	Publication Date	Title
DK2041093T3 (da)	2010-08-02	Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
FR22C1024I2 (fr)	2023-03-24	Derives de pyridazinone
LTC2137143I2 (lt)	2023-10-10	Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
DK3456707T3 (da)	2020-07-20	4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2300443T3 (da)	2013-02-18	Triazolderivater, der er anvendelige til behandling af sygdomme
HUS1600048I1 (hu)	2017-01-30	Készítmény Fabry-kór kezelésére
DK1833799T3 (da)	2009-01-19	3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0816116A2 (pt)	2015-03-03	Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2102169T3 (da)	2012-08-27	Indazolylamidderivater til behandling af glucocorticoidreceptormedierede forstyrrelser
SMP200900085B (it)	2010-11-12	3-imidazolil-indoli per il trattamento di malattieproliferative.
DK3309139T3 (da)	2023-12-18	Process for the preparation of 2,3,3,3-trifluoropropene
DE602008005634D1 (de)	2011-04-28	1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
DK2019683T4 (da)	2022-08-29	Indgivelse af vækstfaktorer til behandling af CNS-lidelser
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
DE112007002915A5 (de)	2009-10-15	Verstelleinrichtung
DK1874781T3 (da)	2009-11-02	Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK1879623T3 (da)	2012-12-17	Genterapi til rygmarvssygdomme
DK1928438T3 (da)	2013-04-22	Anvendelse af ibudilast til behandling af stofafhængighed
DK2285808T3 (da)	2014-02-03	Spiroindolderivater til behandling af parasitsygdomme
DK2046802T3 (da)	2013-09-16	2-substituerede methylpenamderivater
DK1937633T3 (da)	2010-10-11	Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
BRPI0916363A2 (pt)	2018-05-29	derivados de 4,5-di-hidro-oxazol-2-ila